Myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy, is a rare, multi-systemic disease similar to but distinct from myotonic dystrophy type-1 (DM1). DM2 has a later onset, usually milder phenotype, and lacks the severe congenital form seen in DM1. The gene defect in DM2 is an unstable CCTG repeat expansion in the *cellular nucleic acid-binding protein* gene (cellular nucleic acid-binding protein---formerly known as *ZNF9* gene).^[@R1]^ Like DM1, DM2 has an autosomal dominant inheritance pattern and expansion lengths of 75 repeats or longer are considered pathogenic.^[@R1]^

The CCTG-expansion is extremely unstable. It increases with age and shows marked heterogeneity in length within different tissues of the same subject.^[@R2]^ Unlike DM1, there is no clear correlation between the length of the CCTG expansion and clinical severity. Symptoms in DM2 patients usually begin in the third to fifth decades of life. No congenital or infantile cases have been reported. Muscular symptoms are usually the major complaints that cause patients to see a physician. However, extramuscular manifestations, such as cataracts, may precede the muscular complaints. Muscle weakness and/or myalgia are the most common symptoms at onset, whereas about 40%--50% of patients initially complain of myotonia/muscle stiffness.^[@R3],[@R4]^ As the duration of DM2 increases many organs and systems may be affected; hence, the patient\'s management should include screening for heart diseases (cardiomyopathy, arrhythmias), diabetes mellitus/insulin resistance, thyroid dysfunctions, cataract, gastrointestinal disturbances, respiratory involvement, mild cognitive disorders, and tumors.^[@R5][@R6][@R8]^ Symptom severity widely varies among patients, even within members of the same family. Age-dependent worsening of muscular symptoms and an increase of the multi-systemic complications has been observed.^[@R4]^

Because of the low diagnosed prevalence of DM2 patients worldwide and the relatively recent discovery of this disease, there is a lack of rigorous evidence regarding the care and management of patients. For this reason, evidence-based guidelines cannot currently be developed. Consensus-based clinical care recommendations can serve as a support and guide for clinicians not familiar with the heterogeneous nature of DM2, enabling quality, standardized patient care for those living with DM2.

Methodology {#s1}
===========

The Myotonic Dystrophy Foundation (MDF) recruited clinicians from the United States and Europe who have experience in the treatment of patients with DM2 to develop consensus-based care recommendations.

The project included a total working group of 15 clinical professionals. MDF provided project design, development, and management support. A complete list of working group members and authors is provided below.

The principles of the single text procedure were mainly adopted to steer the consensus-building process.^[@R9]^ The single text procedure employs the use of a single document as a starting point to incorporate the input and contributions of stakeholders. In this approach, stakeholders add, subtract, and refine a draft text that becomes the foundation for a final ratified document.

This consensus-building model was selected because it could be effective within the context of the limited clinical care data available for DM2, the clinical content already available, and the complexities of working across a large, international group of experts.

Having already developed consensus-based care recommendations for DM1^[@R10]^ and given the similarity of system involvement and management between DM1 and DM2, MDF created a draft document for DM2 based on DM1-consensus care recommendations (for further methodological details, refer to the Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1, 2018, [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources))).

MDF circulated the draft document to working group members who read the draft content and provided their recommendations. MDF aggregated all the revisions and suggestions into a single updated document. Recommendations in conflict were circulated within the group for discussion and resolved through serial conference calls.

These efforts led to the final consensus-based care recommendations and Quick Reference Guide for DM2, which were completed in mid-2018. The Quick Reference Guide content is provided as an appendix, and the full document is available online (appendix e-1, [links.lww.com/CPJ/A88](http://links.lww.com/CPJ/A88)). Both feature flowcharts and other infographics for ease of use.

Results {#s2}
=======

See full recommendations at [Neurology.org/cp](http://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000645).

Life-threatening symptoms---Clinical care recommendations {#s2-1}
---------------------------------------------------------

• Cardiovascular management◦ DM2-related cardiac pathophysiology, although affecting all myocardial tissues, preferentially targets the cardiac conduction system. Conduction system defects are progressive and, although initially asymptomatic, increase the risk for symptomatic arrhythmias.◦ Significant cardiac involvement that subsequently leads to adverse cardiac events is often asymptomatic.◦ At diagnosis, check for cardiac symptoms, perform a 12-lead ECG, and consider a 24-hour Holter ECG.◦ Conduction abnormalities on a standard 12-lead ECG including sinus rate \< 50 beats per minute, PR interval \> 200 ms, QRS duration \> 100 ms, left anterior or posterior fascicular block, abnormal Q-waves, atrial tachycardia, fibrillation, or flutter, and ventricular arrhythmias are indicative of cardiac involvement.◦ Refer patients with cardiac symptoms, abnormal annual 12-lead ECG indicative of cardiac involvement, and patients older than 40 years without previous cardiac evaluation to a cardiologist for further evaluation.◦ See Flowchart figure 1 in Quick Reference Guide (appendix, [links.lww.com/CPJ/A87](http://links.lww.com/CPJ/A87)).◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Respiratory management◦ Some DM2 patients have significant breathing problems that can result from muscle weakness of the diaphragm, abdominal and intercostal muscles, and myotonia of these muscles, leading to poor ventilatory force and resulting in low blood oxygen and elevated blood carbon dioxide levels.◦ Clinicians must look for respiratory symptoms in DM2 patients.◦ In asymptomatic patients, a pulmonary function assessment every 2 years is recommended.◦ Refer DM2 patients with respiratory symptoms including ineffective cough (normal peak expiratory cough flow rate is \>270 L/min), respiratory insufficiency, recurrent pulmonary infections, prominent snoring, and maximal inspiratory pressure \<60 cmH~2~O or forced vital capacity values of 50% less than predicted normal values to a pulmonologist knowledgeable in neuromuscular disorders.◦ Vaccinate for pneumonia and flu; treat respiratory infections quickly and use cough assistance and mechanical ventilation as needed along with obtaining consultations from respiratory therapy and pulmonary medicine groups.◦ Some patients will eventually require nighttime ventilator support. Most patients with chronic respiratory insufficiency respond to noninvasive ventilatory support (NIV).◦ For chronic respiratory insufficiency, use supplemental oxygen with caution and in conjunction with NIV.◦ If surgery is planned, reassess clearance capacity if needed, possible adaptation to NIV or cough assistance.◦ See Flowchart figure 2 in Quick Reference Guide (appendix, [links.lww.com/CPJ/A87](http://links.lww.com/CPJ/A87)).◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).

Severe symptoms---Clinical care recommendations {#s2-2}
-----------------------------------------------

• Pain control◦ Muscle pain can occur in the neck, back, shoulders, hip flexors, and lower limbs. Statin-induced myopathy is often accompanied by muscle pain.◦ Treat with conventional pain medications, which may be useful in treating the painful aspects of myotonic dystrophy (e.g., Ibuprofen).◦ Opioids can be used but should be avoided if possible. If implemented, low doses should be used with close monitoring for side effects (see Anesthesia and surgery).◦ Other remedies, such as massage, nerve blocks, heat/ice, or chiropractic can be used. Some patients have reported that cannabis, cannabinoids, or phytocannabinoids ease pain; however, this needs to be proven in controlled clinical trials.◦ Refer to Physical Therapy or Occupational Therapy if conventional treatment is not successful.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Skeletal muscle weakness and rehabilitation Skeletal muscle weakness and myalgia are major features of DM2.◦ Initial weakness is in proximal hip girdle and neck (flexors \> extensors) muscles. Axial muscle weakness is frequent in DM2 and may result in lower back pain.◦ The progression is relatively slow, 1%--3% percent per year.◦ Mild ptosis might be occasionally present. Calf hypertrophy may occur.◦ Myalgia can be the most prominent clinical feature in the early stages and may severely affect occupational performance.◦ Impacts to employment and activities of daily living occur because of the proximal and axial muscle weakness (e.g., climbing stairs and standing up from the floor)◦ Treat with moderate- or low-intensity aerobic and resistance exercise, orthoses, or braces. It is advised to obtain a cardiac evaluation before starting a new exercise routine.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Skeletal muscle myotonia◦ Myotonia---a sustained muscle contraction and difficulty in relaxing muscles---may occur and be symptomatic in DM2 patients.◦ Myotonia can contribute to muscle stiffness, pain, prolonged hand grip, speech and swallowing difficulties, and gastrointestinal issues.◦ Mexiletine may be considered in select patients for myotonia treatment of the hands with appropriate cardiac monitoring.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources)• Ocular symptoms◦ Major and clinically relevant eye manifestations in DM2 can include the following: cataracts, eyelid ptosis and incomplete eyelid closure, retinal changes and changes in intraocular pressure.◦ Bilateral eyelid ptosis is a rare feature of DM2, but can occur in some patients.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Gastrointestinal symptoms◦ Limited information is available, and manifestations are less severe than in DM1.◦ Ask about problems with chewing, swallowing, drooling, reflux, bloating, abdominal pain, bowel movement frequency and characteristics, diarrhea, and incontinence.◦ Physical examination should include abdominal palpation, including around gall bladder, and rectal examination for anal sphincter spasm and dyssynergic defecation for symptomatic patients.◦ DM2 patients are at risk for pseudo-obstruction and experience other problems that may cause actual obstruction of small or large intestine, including endometriosis, acute gallbladder inflammation, ruptured ovarian cysts, and sigmoid volvulus. Monitor potential obstructions to determine whether they are pseudo or actual and treat accordingly.◦ Nonmedical interventions:⁃ High-fiber diet for diarrhea or constipation; increase water intake⁃ Nutritional supplement for weight loss, weight gain, or dysphagia⁃ Dysphagia therapy referral for oral pharyngeal dysphagia◦ Possible medical interventions:⁃ Loperamide for diarrhea control⁃ Laxatives for constipation:◦ *First-line therapy*: Miralax, Senna, Ducosate, or Linaclotid◦ *Second-line therapy*: Bisacodyl, Lubiprostone, or Linaclotide⁃ Metoclopramide for gastroparesis, pseudo-obstruction, reflux⁃ Antibiotics for bacterial overgrowth-induced diarrhea (based on breath testing)⁃ Enteral feeding only for recurring pneumonia or severe dysphagia causing weight loss or causing inability to swallow safely without recurrent aspiration⁃ Mexiletine may be considered to treat diarrhea or constipation in DM2; however, its use for these indications requires further study.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Neuropsychiatric symptoms◦ Advise patients that DM2 is also a "brain disorder" that can involve cognitive deficits and changes in cognition over time.◦ Include psychiatric and behavioral examination at baseline and during regularly scheduled follow-up appointments or when symptoms appear.◦ Refer patients with psychiatric or behavioral disorders and patients with cognitive complaints to a mental health care professional for testing and follow-up; patients may have limited insight into these issues---consider input from partners and family members as appropriate.◦ Treat with psychostimulants if apathy is associated with an impairing level of fatigue or excessive daytime sleepiness (EDS) (see Excessive daytime sleepiness) or antidepressant medication (cardiac examination before starting treatment, including a 12-lead ECG).◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Excessive Daytime Sleepiness symptoms◦ EDS is very rare in DM2 but can be a life-altering symptom. In contrast, fatigue is relatively common in DM2 and may be seriously disabling.◦ Assess for EDS with Epworth Sleepiness Scale or similar standardized questionnaire instrument; prescribe sleep study if sleep disturbance is suspected.◦ Monitor periodic limb movements (muscle activity during sleep), as well as EEG, and respiratory measures during sleep study to assess possible obstructive sleep apnea and CNS-mediated sleep apnea.◦ Refer to pulmonologist and/or sleep specialist if EDS scores are positive on scales.◦ Question patients regarding alcohol or caffeine consumption, medications, and sleep habits for contribution to EDS.◦ Evaluate effect of possible respiratory muscle weakness (forced vital capacity value, sitting and supine) on presence of EDS.◦ If nocturnal or daytime hypoventilation is suspected, consider noninvasive positive pressure ventilation, and refer to a pulmonologist with experience in neuromuscular diseases regarding possible need for NIV.◦ Consider modafinil for treatment if coexisting CNS alteration is suspected as the cause for EDS.◦ Consider cognitive behavioral therapy or behavioral therapy for apathy; also help treat fatigue; psychostimulant treatment can be considered if apathy is associated with an impairing level of fatigue or EDS.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Endocrine and metabolic symptoms◦ Follow criteria from American Diabetes Association regarding the type of initial testing to obtain, typically fasting blood glucose or HbA1c and if symptomatic diabetes is suspected.◦ Consider formal glucose tolerance testing to monitor glucose control in patients; request serial measurement of HbA1c and fasting plasma glucose annually and coordinate care with diabetes specialist as necessary.◦ Consider treating insulin resistance with lifestyle changes in diet and exercise.◦ Measure liver and bilirubin levels at baseline and annually; chronic liver enzyme elevation is typical and does not necessarily indicate the need for obtaining a liver biopsy.◦ Request thyroid-stimulating hormone (TSH) and circulating thyroid hormone (TSH and Free T4) level tests at baseline and at least every 3 years; more frequently if indicated.◦ Test for hyperlipidemia using serum blood lipid levels at baseline and every 3 years; more frequently if indicated. Treat hyperlipidemia per current practice.◦ Gender-specific recommendations:⁃ Women: Inquire about painful or irregular menses; ovarian cysts; endometriosis, reproductive history.⁃ Men: Inquire about erectile dysfunction; consider further workup and medications to treat erectile dysfunction. Consider possible cardiovascular risks---side effects associated with some erectile dysfunction medications (over the counter and prescribed).⁃ Inquire about infertility and family planning.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Tumors◦ Follow general population cancer screening guidelines, particularly for breast, testicular, cervical, and colon cancer.◦ Evaluate suspicious new CNS, abdominopelvic and thyroid symptoms for possible cancer; consider cancers of the brain, uterus, and ovary.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Pregnancy and obstetric management◦ The effects of DM2 on both smooth and striated muscle can complicate pregnancy, labor and delivery, and increase myotonia.◦ Prenatal and preimplantation genetic diagnosis can allow for termination of the pregnancy or selective implantation of unaffected embryos if desired.◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).• Surgery, anesthesia, and pain◦ Although a higher incidence of adverse reactions to medications used for anesthesia and analgesia has been reported for DM1 (about 8%), it is yet not clear whether similar risks occur also in DM2 patients. However, given this uncertainty and the potentially serious complications reported in some DM2 patients, our advice is to adopt similar anesthesia guidelines as suggested for DM1.◦ See MDF*\'s Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient* ([myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources))) for anesthesia risks and recommendations *before any surgeries or procedures requiring anesthesia.*◦ See full recommendations at [myotonic.org/clinical-resources](http://www.myotonic.org/clinical-resources).

Conclusions {#s3}
===========

These consensus-based care recommendations for patients with DM2 are the product of an international group of experienced clinicians. They are intended to lead to more informed and prepared clinical professionals and more readily available and high-quality care for affected families.

This project would not have been possible without the major commitment made by the 15 international professionals involved in its development. MDF team leads included Paul Formaker, Leah Hellerstein, and Molly White.
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